PPMD's Blog – March 2012 Archive (4)

Prosensa’s Clinical Development Plan Update – March 2012

In parallel to the on-going development of the lead compound PRO051/GSK2402968, which is being developed by GSK with an active involvement of Prosensa, there are five more compounds for Duchenne in Prosensa’s pipeline.  Below you can find an update about the current state of development of these compounds.



Prosensa is currently conducting a clinical study to investigate the effect of PRO044 in boys with Duchenne muscular dystrophy, who have a dystrophin gene mutation amenable to…

Continue

Added by PPMD on March 26, 2012 at 9:41am — 10 Comments

Important Webinar: AVI Clinical Trial Update

AVI Clinical Trial Update

Parent Project Muscular Dystrophy presents an AVI webinar on Wednesday, March 21 at 1pm eastern. The webinar will cover a pre-data update on AVI BioPharma's Phase IIb study evaluating eteplirsen for the treatment of Duchenne patients with mutations amenable to exon-51 skipping, and will be lead by Chris Garabedian, the CEO of AVI…

Continue

Added by PPMD on March 19, 2012 at 2:30pm — No Comments

Reminder: Register Today for 2012 West Coast Connect Meeting

By now we hope you have heard that Parent Project Muscular Dystrophy will be hosting our first West Coast Connect Meeting, April 13-15, 2012 in San Diego, CA at the…

Continue

Added by PPMD on March 7, 2012 at 10:00am — No Comments

Vote for Duchenne in the 2012 Neuro Film Festival!

The trailer for "Duchenne With A Future: The Power To Live," a documentary about the success factors of living an adult life with Duchenne, has been entered into the American Academy of Neurology's 2012 Neuro Film Festival! By enrolling we hope to promote research and raise Duchenne awareness.…



Continue

Added by PPMD on March 6, 2012 at 7:00pm — 1 Comment

Monthly Archives

2018

2017

2016

2015

2014

2013

2012

2011

2010

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service